Items per page
Sort by

Send to:

Choose Destination

Results: 14

Cited In for PubMed (Select 17975013)


Activating c-KIT mutations confer oncogenic cooperativity and rescue RUNX1/ETO-induced DNA damage and apoptosis in human primary CD34+ hematopoietic progenitors.

Wichmann C, Quagliano-Lo Coco I, Yildiz Ö, Chen-Wichmann L, Weber H, Syzonenko T, Döring C, Brendel C, Ponnusamy K, Kinner A, Brandts C, Henschler R, Grez M.

Leukemia. 2015 Feb;29(2):279-89. doi: 10.1038/leu.2014.179. Epub 2014 Jun 4.


ETV6/RUNX1 induces reactive oxygen species and drives the accumulation of DNA damage in B cells.

Kantner HP, Warsch W, Delogu A, Bauer E, Esterbauer H, Casanova E, Sexl V, Stoiber D.

Neoplasia. 2013 Nov;15(11):1292-300.


Transcription factor RUNX1 promotes survival of acute myeloid leukemia cells.

Goyama S, Schibler J, Cunningham L, Zhang Y, Rao Y, Nishimoto N, Nakagawa M, Olsson A, Wunderlich M, Link KA, Mizukawa B, Grimes HL, Kurokawa M, Liu PP, Huang G, Mulloy JC.

J Clin Invest. 2013 Sep;123(9):3876-88. doi: 10.1172/JCI68557. Epub 2013 Aug 27. Erratum in: J Clin Invest. 2013 Nov 1;123(11):4979.


AML1-ETO mediates hematopoietic self-renewal and leukemogenesis through a COX/β-catenin signaling pathway.

Zhang Y, Wang J, Wheat J, Chen X, Jin S, Sadrzadeh H, Fathi AT, Peterson RT, Kung AL, Sweetser DA, Yeh JR.

Blood. 2013 Jun 13;121(24):4906-16. doi: 10.1182/blood-2012-08-447763. Epub 2013 May 3.


Acute B lymphoblastic leukaemia-propagating cells are present at high frequency in diverse lymphoblast populations.

Rehe K, Wilson K, Bomken S, Williamson D, Irving J, den Boer ML, Stanulla M, Schrappe M, Hall AG, Heidenreich O, Vormoor J.

EMBO Mol Med. 2013 Jan;5(1):38-51. doi: 10.1002/emmm.201201703. Epub 2012 Dec 11.


Targeting autophagic pathways for cancer drug discovery.

Liu B, Bao JK, Yang JM, Cheng Y.

Chin J Cancer. 2013 Mar;32(3):113-20. doi: 10.5732/cjc.012.10010. Epub 2012 Jul 26. Review.


Thrombopoietin/MPL participates in initiating and maintaining RUNX1-ETO acute myeloid leukemia via PI3K/AKT signaling.

Pulikkan JA, Madera D, Xue L, Bradley P, Landrette SF, Kuo YH, Abbas S, Zhu LJ, Valk P, Castilla LH.

Blood. 2012 Jul 26;120(4):868-79. doi: 10.1182/blood-2012-03-414649. Epub 2012 May 21.


Contribution of an aged microenvironment to aging-associated myeloproliferative disease.

Vas V, Wandhoff C, Dörr K, Niebel A, Geiger H.

PLoS One. 2012;7(2):e31523. doi: 10.1371/journal.pone.0031523. Epub 2012 Feb 21.


The thrombopoietin/MPL/Bcl-xL pathway is essential for survival and self-renewal in human preleukemia induced by AML1-ETO.

Chou FS, Griesinger A, Wunderlich M, Lin S, Link KA, Shrestha M, Goyama S, Mizukawa B, Shen S, Marcucci G, Mulloy JC.

Blood. 2012 Jul 26;120(4):709-19. doi: 10.1182/blood-2012-01-403212. Epub 2012 Feb 14.


Acute myeloid leukemia with the t(8;21) translocation: clinical consequences and biological implications.

Reikvam H, Hatfield KJ, Kittang AO, Hovland R, Bruserud Ø.

J Biomed Biotechnol. 2011;2011:104631. doi: 10.1155/2011/104631. Epub 2011 May 3.


N-Ras(G12D) induces features of stepwise transformation in preleukemic human umbilical cord blood cultures expressing the AML1-ETO fusion gene.

Chou FS, Wunderlich M, Griesinger A, Mulloy JC.

Blood. 2011 Feb 17;117(7):2237-40. doi: 10.1182/blood-2010-01-264119. Epub 2011 Jan 3.


In vitro transformation of primary human CD34+ cells by AML fusion oncogenes: early gene expression profiling reveals possible drug target in AML.

Abdul-Nabi AM, Yassin ER, Varghese N, Deshmukh H, Yaseen NR.

PLoS One. 2010 Aug 27;5(8):e12464. doi: 10.1371/journal.pone.0012464.


Core binding factor at the crossroads: determining the fate of the HSC.

Link KA, Chou FS, Mulloy JC.

J Cell Physiol. 2010 Jan;222(1):50-6. doi: 10.1002/jcp.21950. Review.


Mouse models of human AML accurately predict chemotherapy response.

Zuber J, Radtke I, Pardee TS, Zhao Z, Rappaport AR, Luo W, McCurrach ME, Yang MM, Dolan ME, Kogan SC, Downing JR, Lowe SW.

Genes Dev. 2009 Apr 1;23(7):877-89. doi: 10.1101/gad.1771409.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk